More than $50M raised by publicly traded drug developer
A public biopharmaceutical company headquartered in Dallas has secured $53 million in private financing to continue development of a drug for autoimmune-related diseases.
Categories
Recent Posts
The Farm in Allen adds more office tenants
Texas Regional Bank market exec departs
Shotgun House's next act: Reinvigorate the space and expand the brand
New Urban Air opens near Heights with another planned in Rosenberg (PHOTOS)
Bankruptcy court approves Sunnova's initial asset sales as company files plans for more
Centurion American buys land for 2,000-acre project in Grayson County
Homebuilder begins sales at 1,000-home community north of Dallas
Austin well positioned to grow its defense industry
Hutto holds on highway expansion that may have hurt shopping center
New ER planned to serve Manor's growing population